Guideline-directed heart failure medication should be optimized for at least 3–6 months, including modern strategies as ARNI and SGLT2 inhibitors before re-evaluating the need for CRT using echocardiography and the clinical estimation [5]. This evidence concerns the gene SLC5A2 and heart failure.